SCHEMBL9975498

SCHEMBL9975498

COC(=O)Cc1ccc2c(c1)OC(C)(C)O2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
GAA P10253 1/20 0.49
GFER P55789 1/20 0.49
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46
HSP90AB1 P08238 1/20 0.45
SMN1; SMN2 Q16637 5/20 0.44
NPC1 O15118 5/20 0.44
RAB9A P51151 4/20 0.44
HPGD P15428 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
TSHR P16473 3/20 0.43
MAPT P10636 2/20 0.43
PDK2 Q15119 1/20 0.42
CHEK1 O14757 1/20 0.42
SLC7A5 Q01650 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31490121 1.00 ALDH1A1 (0.49) ALDH1A1GAAGFERALOX15ALOX12
SCHEMBL11888516 0.85 ALOX15 (0.45) ALOX15ALOX12CYP4F2CYP4A11SMN1; SMN2
SCHEMBL7153462 0.83 ALOX15 (0.51) ALDH1A1GAAALOX15ALOX12SMN1; SMN2
SCHEMBL12367132 0.82 ALOX15 (0.50) ALDH1A1GAAALOX15ALOX12SMN1; SMN2
SCHEMBL25494165 0.79 ALOX15 (0.40) ALDH1A1ALOX15ALOX12SMN1; SMN2NPC1
SCHEMBL13384485 0.77 ALOX15 (0.56) ALDH1A1ALOX15ALOX12SMN1; SMN2NPC1
SCHEMBL30523664 0.77 HIF1A (0.46) ALDH1A1GAAGFERCYP4F2CYP4A11
SCHEMBL20766930 0.77 HIF1A (0.46) ALDH1A1GAAGFERCYP4F2CYP4A11
SCHEMBL19926744 0.76 SMN1; SMN2 (0.57) ALDH1A1GAAGFERALOX15SMN1; SMN2
SCHEMBL1744784 0.76 SMN1; SMN2 (0.64) ALDH1A1SMN1; SMN2NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023078464-A1 EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF 上海弼领生物技术有限公司 2023-05-11 WO disclosed
WO-2019171088-A1 BIOISPIRED PROTEASOME ACTIVATORS WITH ANTIAGEING ACTIVITY NATIONAL HELLENIC RESEARCH FOUNDATION (GR) 2019-09-12 WO disclosed
EP-2666761-A1 HYDROXYTYROSOL ETHERS Fundacio Imim (ES) 2013-11-27 EP disclosed
US-20130267588-A1 HYDROXYTYROSOL ETHERS FUNDACIO IMIM (ES) 2013-10-10 US disclosed
US-20130267588-A1 HYDROXYTYROSOL ETHERS FUNDACIO IMIM (ES) 2013-10-10 US disclosed
US-20130267588-A1 HYDROXYTYROSOL ETHERS FUNDACIO IMIM (ES) 2013-10-10 US disclosed
WO-2012080555-A1 HYDROXYTYROSOL ETHERS FUNDACIÓ IMIM (ES) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267588-A1 HYDROXYTYROSOL ETHERS CNR1, CNR2, HCRTR1 ALDH1A1 1182/4885GAA 3445/4885GFER 867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.